Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Join Us
    • Values & Culture
    • Perks & Benefits
    • Explore Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Aptose To Release First Quarter Ended March 31, 2019 Financial Results and Hold Conference Call on May 7, 2019

Apr 23, 2019 7:30am EDT

Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Apr 02, 2019 7:00am EDT

Aptose Presents New Preclinical Data on CG-806 and APTO-253 at the 2019 AACR Annual Meeting

Apr 01, 2019 1:00pm EDT

Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806

Mar 25, 2019 7:02am EDT

Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018

Mar 12, 2019 4:02pm EDT

Aptose to Participate in Upcoming Investor Conferences in March 2019

Mar 07, 2019 7:00am EST

Aptose Biosciences and CrystalGenomics Announce Issuance of Australian Patent for CG-806

Mar 04, 2019 7:00am EST

Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting

Feb 28, 2019 7:00am EST

Aptose To Release Fourth Quarter and Year End December 31, 2018 Financial Results and Hold Conference Call on March 12, 2019

Feb 26, 2019 7:30am EST

Aptose Biosciences Submits IND Application for CG-806

Feb 25, 2019 7:00am EST
RSS
  • Prev
    • 1...
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • ...32
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Clinical Trials Policy Disclaimer Sitemap Manage Cookie Preferences